Zacks Investment Research downgraded Aerie Pharmaceuticals Inc (NASDAQ:AERI) to Sell in a report released today.
- Updated: October 4, 2016
Yesterday Aerie Pharmaceuticals Inc (NASDAQ:AERI) traded 0.71% higher at $38.17. The company’s 50-day moving average is $26.22 and its 200-day moving average is $18.80. The last closing price is up 103.61% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 658,551 shares of the stock traded hands, down from an average trading volume of 1,087,780
Zacks Investment Research has downgraded Aerie Pharmaceuticals Inc (NASDAQ:AERI) to Sell in a report released on Tuesday October 04, 2016.
Previously on Tuesday September 20, 2016, HC Wainwright reported on Aerie Pharmaceuticals Inc (NASDAQ:AERI) increased the target price from $0.00 to $66.00. At the time, this indicated a possible upside of 0.94%.
See Chart Below
Aerie Pharmaceuticals Inc has a 52 week low of $10.82 and a 52 week high of $41.72 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 7 brokers have issued a report on the company. The average stock price target is $45.71 with 3 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.